France Interventional Oncology Market Size, Share, and COVID-19 Impact Analysis, By Technique (Ablation Therapies, Embolization Therapies, Biopsy Techniques, Targeted Therapy Delivery Systems, Image-Guided Procedures, and Others), By Application (Liver Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer, Breast Cancer, and Others), By End Use (Hospitals and Specialty Clinics) and France Interventional Oncology Market Insights, Industry Trend, Forecasts to 2035

France Interventional Oncology Market Insights Forecasts to 2035

• The France Interventional Oncology Market Size Was Estimated at USD 83.5 Million in 2024.
• The France Interventional Oncology Market Size is Expected to Grow at a CAGR of Around 8.98% from 2025 to 2035.
• The France Interventional Oncology Market Size is Expected to Reach USD 214.9 Million by 2035.

According to a research report published by Spherical Insights & Consulting, the France Interventional Oncology Market size is anticipated to reach USD 214.9 million by 2035, growing at a CAGR of 8.98% from 2025 to 2035. The France interventional oncology market is driven by the rising incidence of cancers, growing preference for minimally invasive procedures, technological advancements in ablative and embolization therapies, an aging population, supportive healthcare infrastructure, and increased early diagnosis and awareness, boosting the adoption of image-guided treatments.

Market Overview

These are the procedures that aim at eliminating or blocking tumors without the need for open surgery, and, therefore, they bring the patient reduced risks of complications, shorter lengths of hospital stay, and faster recuperation. The market comprises medical devices, imaging equipment, consumables, and related technologies that are used in interventional oncology. The increasing number of patients is the main cause of the demand for less invasive interventional oncology techniques, such as ablation and embolization, which are effective in tumor treatment, allow a quicker recovery, and reduce hospital stay.

Report Coverage

This research report categorizes the France interventional oncology market based on various segments and regions, forecasting revenue growth and analyzing trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the France interventional oncology market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the France interventional oncology market.

Driving Factors

The use of advanced image-guided technologies, robotics, and precision devices has not only enhanced the results but also expanded the clinical applications. Besides, a well-developed healthcare system, an aging population, and growing awareness of patients and physicians are some of the factors that help to accelerate the adoption.

Market Segmentation

The France interventional oncology market share is categorized by technique, application, and end use.

• The ablation therapies segment accounted for the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The France interventional oncology market is segmented by technique into ablation therapies, embolization therapies, biopsy techniques, targeted therapy delivery systems, image-guided procedures, and others. Among these, the ablation therapies segment accounted for the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The ablation therapies segment's growth is due to its minimally invasive nature, effectiveness in treating a wide range of tumors, shorter recovery times, and lower risk of complications compared to conventional surgery. Additionally, technological advancements in radiofrequency, microwave, and cryoablation devices, along with increasing adoption by healthcare providers and patient preference for less invasive treatments, are driving the segment’s expansion in the France interventional oncology market.

• The liver cancer segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.  

The France interventional oncology market is segmented by application liver cancer, lung cancer, kidney cancer, prostate cancer, breast cancer, and others. Among these, the liver cancer segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The liver cancer segmental growth is driven by the high prevalence of liver cancer in France, the effectiveness of interventional oncology procedures such as ablation and embolization in treating liver tumors, and the preference for minimally invasive treatments that reduce hospital stays and complications. Advances in image-guided technologies and targeted therapies further enhance treatment precision and patient outcomes, boosting adoption in clinical practice.

• The hospitals segment held the largest market share in 2024 and is anticipated to grow at a substantial CAGR during the forecast period.  

The France interventional oncology market is segmented by end use into hospitals and specialty clinics. Among these, the hospitals segment held the largest market share in 2024 and is anticipated to grow at a substantial CAGR during the forecast period. The hospital's segmental growth is due to the availability of advanced infrastructure, skilled specialists, and comprehensive diagnostic and therapeutic facilities required for interventional oncology procedures. Hospitals also benefit from higher patient volumes, established reimbursement mechanisms, and the capability to offer a wide range of minimally invasive treatments, making them the preferred choice for both physicians and patients in France.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the France interventional oncology market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Guerbet
• EDAP TMS S.A.
• Medtronic plc
• Boston Scientific Corporation
• AngioDynamics, Inc.
• Siemens Healthineers AG
• Johnson & Johnson (Ethicon)
• Merit Medical Systems, Inc.
• Cook Medical
• GE Healthcare
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the France, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the France Interventional Oncology Market based on the below-mentioned segments:

France Interventional Oncology Market, By Technique

• Ablation Therapies
• Embolization Therapies
• Biopsy Techniques
• Targeted Therapy Delivery Systems
• Image-Guided Procedures
• Others

France Interventional Oncology Market, By Application

• Liver Cancer
• Lung Cancer
• Kidney Cancer
• Prostate Cancer
• Breast Cancer
• Others

France Interventional Oncology Market, By End Use

• Hospitals
• Specialty Clinics